Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 3 of 112, showing 5 Applications out of 559 total, starting on record 11, ending on 15

# Protocol No Study Title Investigator(s) & Site(s)

11.

ECCT/25/08/06   MK-8527-010
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women   
Principal Investigator(s)
1. Irene Wambui Inwani
Site(s) in Kenya
1. UW-KNH; Rachuonyo County Hospital, Oyugis (Homa Bay county)
2. KEMRI-CMR-RCTP KEMRI CIS Building (Kisumu county)
3. Kargeno Research & Policy Hub (Kisumu county)
4. KEMRI-CCR-PHRD, Thika site (Kiambu county)
 
View

12.

ECCT/25/08/05   Floral roll over study
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Dr. Isaac Tsikhutsu
Site(s) in Kenya
1. KEMRI WALTER REED KERICHO (Kericho county)
2. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrudes Childrens Hospital (Nairobi City county)
5. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
7. KEMRI Kondele Children\'s Hospital (Kisumu county)
 
View

13.

ECCT/25/08/04   MK-8527-010 PrEP
    A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral MK-8527 Once-Monthly as HIV-1 Preexposure Prophylaxis in Cisgender Women    
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
1. KEMRI-CCR PHRD Thika (Kiambu county)
 
View

14.

ECCT/25/08/03   Cabotegravir + Rilpivirine Lon
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human   Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long acting Combination Therapy Studies   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Aga Khan University Hospital (Nairobi City county)
2. Moi University Clinical Research Centre (Uasin Gishu county)
3. KEMRI-WRP (Kericho county)
4. Kenyatta National Hospital Comprehensive Care Centre (Nairobi City county)
 
View

15.

ECCT/25/08/02   MK-8527-010
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women.   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
1. KEMRI CMR RCTP (Kisumu county)
 
View